Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

DaPeCa-4: outcome in penile cancer patients with N3 disease due to extra nodal extension treated with surgery and chemo-irradiation

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Short-term morbidity and mortality following radical cystectomy: a systematic review

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Surgical Management of Muscle Invasive Bladder Cancer: A Review of Current Recommendations

    Research output: Contribution to journalReviewResearchpeer-review

View graph of relations

Objective: The role of pelvic lymph node dissection (PLND) is still debated in patients with N3 stage penile cancer. In Denmark this subgroup of patients is in general managed with an inguinal lymphadenectomy (ILND) and adjuvant chemoradiation and PLND is not offered as a standard. The objective of this study was to report treatment outcomes of this regimen and compare this with existing literature.Materials and methods: We retrospectively reviewed records of patients with pT1-T4, N3, M0 penile cancer diagnosed between 1st January 2010 and 31th December 2014 in Denmark and treated with curative intend.Results: 21 patients were identified with a median follow up of 74 months (CI 54-94). Management of the penile lesion was local resection in 5 (23.8%), partial penectomy in 10 (47.6%), and total penectomy in 6 (28.6%) of patients. Regarding the most extensive lymph node (LN) surgery: 4 patients (23,8%) went directly to oncological treatment from sentinel node biopsy with no further LN dissection, 6 patients (28.6%) were treated with unilateral ILND, 10 patients (47.6%) with bilateral ILND and a single patient (4.8%) was treated with ILND and PLND. In the adjuvant setting patients were treated with external beam therapy of involved regions and cisplatin-based chemotherapy. Median overall survival was 84 months (CI 0-176). The 5-year probability of surviving penile cancer was 57.1% (CI 36.0-78.3).Conclusion: Treatment with surgery and chemo-irradiation in this national cohort does not show inferior survival outcomes compared to historical cohorts.

Original languageEnglish
JournalScandinavian Journal of Urology
Issue number4
Pages (from-to)334-338
Number of pages5
Publication statusPublished - 17 Jun 2020

    Research areas

  • adjuvant therapy, lymph node dissection, overall survival, Penile cancer, prognosis

ID: 60879740